Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2004 2
2006 1
2008 3
2009 1
2010 1
2012 1
2013 1
2014 4
2015 1
2016 2
2017 1
2018 1
2019 1
2020 6
2021 3
2022 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Sexual dimorphism in the white matter of rodents.
Cerghet M, Skoff RP, Swamydas M, Bessert D. Cerghet M, et al. J Neurol Sci. 2009 Nov 15;286(1-2):76-80. doi: 10.1016/j.jns.2009.06.039. Epub 2009 Jul 22. J Neurol Sci. 2009. PMID: 19625027 Free PMC article. Review.
Review of the COVID-19 Risk in Multiple Sclerosis.
Chaudhry F, Jageka C, Levy PD, Cerghet M, Lisak RP. Chaudhry F, et al. Among authors: cerghet m. J Cell Immunol. 2021;3(2):68-77. doi: 10.33696/immunology.3.080. J Cell Immunol. 2021. PMID: 33959727 Free PMC article.
Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target.
Zahoor I, Suhail H, Datta I, Ahmed ME, Poisson LM, Waters J, Rashid F, Bin R, Singh J, Cerghet M, Kumar A, Hoda MN, Rattan R, Mangalam AK, Giri S. Zahoor I, et al. Among authors: cerghet m. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2123265119. doi: 10.1073/pnas.2123265119. Epub 2022 Jun 14. Proc Natl Acad Sci U S A. 2022. PMID: 35700359 Free PMC article.
Pro-resolution lipid mediator maresin-1 ameliorates inflammation, promotes neuroprotection, and prevents disease progression in experimental models of multiple sclerosis.
Zahoor I, Nematullah M, Ahmed ME, Fatma M, Mir S, Ayasolla K, Cerghet M, Palaniyandi S, Mao-Draayer Y, Rattan R, Giri S. Zahoor I, et al. Among authors: cerghet m. bioRxiv [Preprint]. 2023 Sep 26:2023.09.25.559216. doi: 10.1101/2023.09.25.559216. bioRxiv. 2023. PMID: 37808700 Free PMC article. Preprint.
Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism.
Fitzgerald KC, Smith MD, Kim S, Sotirchos ES, Kornberg MD, Douglas M, Nourbakhsh B, Graves J, Rattan R, Poisson L, Cerghet M, Mowry EM, Waubant E, Giri S, Calabresi PA, Bhargava P. Fitzgerald KC, et al. Among authors: cerghet m. Cell Rep Med. 2021 Oct 19;2(10):100424. doi: 10.1016/j.xcrm.2021.100424. eCollection 2021 Oct 19. Cell Rep Med. 2021. PMID: 34755135 Free PMC article.
35 results